Search

Your search keyword '"Burchell, Ann N."' showing total 403 results
Start Over Author "Burchell, Ann N." Search Limiters Full Text
403 results on '"Burchell, Ann N."'

5. Antibody neutralization capacity after COVID-19 vaccination in people with HIV (CIHR Canadian HIV trials network 328)

Author

Costiniuk, Cecilia T., Singer, Joel, Lee, Terry, Galipeau, Yannick, McCluskie, Pauline S., Arnold, Corey, Langlois, Marc-André, Needham, Judy, Jenabian, Mohammad-Ali, Burchell, Ann N., Samji, Hasina, Chambers, Catharine, Walmsley, Sharon, Ostrowski, Mario, Kovacs, Colin, Tan, Darrell H.S., Harris, Marianne, Hull, Mark, Brumme, Zabrina L., Lapointe, Hope R., Brockman, Mark A., Margolese, Shari, Mandarino, Enrico, Samarani, Suzanne, Vulesevic, Branka, Lebouche, Bertrand, Angel, Jonathan B., Routy, Jean-Pierre, Cooper, Curtis L., and Anis, Aslam H.

Published
2023
Full Text
View/download PDF

9. Antibody neutralization capacity after coronavirus disease 2019 vaccination in people with HIV in Canada

Author

Costiniuk, Cecilia T., Singer, Joel, Lee, Terry, Galipeau, Yannick, McCluskie, Pauline S., Arnold, Corey, Langlois, Marc-André, Needham, Judy, Jenabian, Mohammad-Ali, Burchell, Ann N., Samji, Hasina, Chambers, Catharine, Walmsley, Sharon, Ostrowski, Mario, Kovacs, Colin, Tan, Darrell H.S., Harris, Marianne, Hull, Mark, Brumme, Zabrina L., Lapointe, Hope R., Brockman, Mark A., Margolese, Shari, Mandarino, Enrico, Samarani, Suzanne, Vulesevic, Branka, Lebouché, Bertrand, Angel, Jonathan B., Routy, Jean-Pierre, Cooper, Curtis L., and Anis, Aslam H.

Published
2023
Full Text
View/download PDF

10. COVID‐19 vaccine effectiveness by HIV status and history of injection drug use: a test‐negative analysis

Author

Puyat, Joseph H., Wilton, James, Fowokan, Adeleke, Janjua, Naveed Zafar, Wong, Jason, Grennan, Troy, Chambers, Catharine, Kroch, Abigail, Costiniuk, Cecilia T., Cooper, Curtis L., Lauscher, Darren, Strong, Monte, Burchell, Ann N., Anis, Aslam, and Samji, Hasina

Subjects
Immune response -- Observations, Intravenous drug abuse -- Physiological aspects, HIV infection -- Physiological aspects, Health
Abstract

: Introduction: People living with HIV (PLWH) and/or who inject drugs may experience lower vaccine effectiveness (VE) against SARS‐CoV‐2 infection. Methods: A validated algorithm was applied to population‐based, linked administrative datasets in the British Columbia COVID‐19 Cohort (BCC19C) to ascertain HIV status and create a population of PLWH and matched HIV‐negative individuals. The study population was limited to individuals who received an RT‐PCR laboratory test for SARS‐CoV‐2 between 15 December 2020 and 21 November 2021 in BC, Canada. Any history of injection drug use (IDU) was ascertained using a validated administrative algorithm. We used a test‐negative study design (modified case−control analysis) and multivariable logistic regression to estimate adjusted VE by HIV status and history of IDU. Results: Our analysis included 2700 PLWH and a matched population of 375,043 HIV‐negative individuals, among whom there were 351 and 103,049 SARS‐CoV‐2 cases, respectively. The proportion of people with IDU history was much higher among PLWH compared to HIV‐negative individuals (40.7% vs. 4.3%). Overall VE during the first 6 months after second dose was lower among PLWH with IDU history (65.8%, 95% CI = 43.5–79.3) than PLWH with no IDU history (80.3%, 95% CI = 62.7–89.6), and VE was particularly low at 4–6 months (42.4%, 95% CI = −17.8 to 71.8 with IDU history vs. 64.0%; 95% CI = 15.7–84.7 without), although confidence intervals were wide. In contrast, overall VE was 88.6% (95% CI = 88.2–89.0) in the matched HIV‐negative population with no history of IDU and remained relatively high at 4–6 months after second dose (84.6%, 95% CI = 83.8–85.4). Despite different patterns of vaccine protection by HIV status and IDU history, peak estimates were similar (≥88%) across all populations. Conclusions: PLWH with a history of IDU may experience lower VE against COVID‐19 infection, although findings were limited by a small sample size. The lower VE at 4–6 months may have implications for booster dose prioritization for PLWH and people who inject drugs. The immunocompromising effect of HIV, substance use and/or co‐occurring comorbidities may partly explain these findings., INTRODUCTION People living with HIV (PLWH) and people who inject drugs (PWID) are two populations that often overlap and may experience lower vaccine effectiveness (VE) against COVID‐19 infection. Injection drug [...]

Published
2023
Full Text
View/download PDF

14. Previous Syphilis Not Associated with Neurocognitive Outcomes in People Living with HIV in Ontario, Canada

Author

CHRISTENSEN, Brandon L., Tavangar, Farideh, Kroch, Abigail E., Burchell, Ann N., Rourke, Sean B., Rousseau, Rodney K., Raboud, Janet M., Bekele, Tsegaye, Tan, Darrell H.S., Kroch, Abigail, Burchell, Ann, Cohen, Jeffrey, Cooper, Curtis, Arbess, Gordon, Lavoie, Elizabeth, Loutfy, Mona, Andany, Nisha, Walmsley, Sharon, Silverman, Michael, Borque, Tammy, El-Helou, Phillipe, Gauvin, Holly, Tharao, Wangari, Li, Alan, Craig, Jeffrey, Martinez-Cajas, Jorge, Cotnam, Jasmine, Di Pede, Tony, Adam, Barry, Santibañez, Viviana, Rousseau, Rodney, Ndung’u, Mary, Chen, YiYi, Cameron, Ruth, Brophy, Jason, Bowerman, Aaron, Record, Dane, Muchano, Elisio, Grey, Cornel, Cotnam, Jasmine, Jackson, Randy, Young, Meghan, Stratton, Trevor, Rueda, Sergio, Burchell, Ann, Adam, Barry, Brennan, David, Cooper, Curtis, Hart, Trevor, Betts, Adrian, Loutfy, Mona, O’Brien, Kelly, Mbuagbaw, Lawrence, Giguere, Pierre, Benoit, Anita, Hillier, Sean, Nyambi, Agatha, Light, Lucia, Qureshi, Nahid, Bekele, Tsegaye, Kesler, Maya, Colyer, Sean, O’Brien, Kristen, Obioha, Adanna, Prabhu, Namita, and Groves, Maxwell

Published
2022
Full Text
View/download PDF

16. Correlates of Breakthrough SARS-CoV-2 Infections in People with HIV: Results from the CIHR CTN 328 Study

Author

Costiniuk, Cecilia T., primary, Lee, Terry, additional, Singer, Joel, additional, Galipeau, Yannick, additional, Arnold, Corey, additional, Langlois, Marc-André, additional, Needham, Judy, additional, Jenabian, Mohammad-Ali, additional, Burchell, Ann N., additional, Samji, Hasina, additional, Chambers, Catharine, additional, Walmsley, Sharon, additional, Ostrowski, Mario, additional, Kovacs, Colin, additional, Tan, Darrell H. S., additional, Harris, Marianne, additional, Hull, Mark, additional, Brumme, Zabrina L., additional, Lapointe, Hope R., additional, Brockman, Mark A., additional, Margolese, Shari, additional, Mandarino, Enrico, additional, Samarani, Suzanne, additional, Lebouché, Bertrand, additional, Angel, Jonathan B., additional, Routy, Jean-Pierre, additional, Cooper, Curtis L., additional, and Anis, Aslam H., additional

Published
2024
Full Text
View/download PDF

17. Risk of End-Stage Liver Disease in HIV-Viral Hepatitis Coinfected Persons in North America From the Early to Modern Antiretroviral Therapy Eras

Author

Klein, Marina B, Althoff, Keri N, Jing, Yuezhou, Lau, Bryan, Kitahata, Mari, Re, Vincent Lo, Kirk, Gregory D, Hull, Mark, Kim, H Nina, Sebastiani, Giada, Moodie, Erica EM, Silverberg, Michael J, Sterling, Timothy R, Thorne, Jennifer E, Cescon, Angela, Napravnik, Sonia, Eron, Joe, Gill, M John, Justice, Amy, Peters, Marion G, Goedert, James J, Mayor, Angel, Thio, Chloe L, Cachay, Edward R, Moore, Richard, Research and Design of IeDEA, for the North American AIDS Cohort Collaboration on, Benson, Constance A, Bosch, Ronald J, Boswell, Stephen, Mayer, Kenneth H, Grasso, Chris, Hogg, Robert S, Harrigan, P Richard, Montaner, Julio SG, Samji, Hasina, Brooks, John T, Buchacz, Kate, Gebo, Kelly A, Moore, Richard D, Rodriguez, Benigno, Horberg, Michael A, Jacobsonc, Lisa P, D'Souza, Gypsyamber, Rourke, Sean B, Burchell, Ann N, Rachlis, Anita R, Hunter-Mellado, Robert F, Mayor, Angel M, Deeks, Steven G, Martin, Jeffrey N, Patel, Pragna, Saag, Michael S, Mugavero, Michael J, Willig, James, Eron, Joseph J, Kitahata, Mari M, Crane, Heidi M, Drozd, Daniel R, Haas, David, Bebawy, Sally, Turner, Megan, Justice, Amy C, Dubrow, Robert, Fiellin, David, Gange, Stephen J, Anastos, Kathryn, McKaig, Rosemary G, Freeman, Aimee M, Lent, Carol, Van Rompaey, Stephen E, Morton, Liz, McReynolds, Justin, Lober, William B, and Abraham, Alison G

Subjects
Medical Microbiology, Biomedical and Clinical Sciences, Clinical Sciences, Hepatitis, Emerging Infectious Diseases, Chronic Liver Disease and Cirrhosis, Hepatitis - C, Digestive Diseases, Liver Disease, Hepatitis - B, Sexually Transmitted Infections, Infectious Diseases, HIV/AIDS, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Infection, Good Health and Well Being, Adult, Aged, Alcohol Drinking, Anti-HIV Agents, Canada, Cohort Studies, Coinfection, End Stage Liver Disease, Female, HIV Infections, Hepatitis B, Hepatitis C, Humans, Incidence, Male, Middle Aged, Risk Factors, United States, HIV, hepatitis C virus, hepatitis B virus, coinfection, end-stage liver disease, North American AIDS Cohort Collaboration on Research and Design of IeDEA, North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of IeDEA, Biological Sciences, Medical and Health Sciences, Microbiology, Clinical sciences
Abstract

BackgroundHuman immunodeficiency virus (HIV)-infected patients coinfected with hepatitis B (HBV) and C (HCV) viruses are at increased risk of end-stage liver disease (ESLD). Whether modern antiretroviral therapy has reduced ESLD risk is unknown.MethodsTwelve clinical cohorts in the United States and Canada participating in the North American AIDS Cohort Collaboration on Research and Design validated ESLD events from 1996 to 2010. ESLD incidence rates and rate ratios according to hepatitis status adjusted for age, sex, race, cohort, time-updated CD4 cell count and HIV RNA were estimated in calendar periods corresponding to major changes in antiretroviral therapy: early (1996-2000), middle (2001-2005), and modern (2006-2010) eras.ResultsAmong 34 119 HIV-infected adults followed for 129 818 person-years, 380 incident ESLD outcomes occurred. ESLD incidence (per 1000 person-years) was highest in triply infected (11.57) followed by HBV- (8.72) and HCV- (6.10) coinfected vs 1.27 in HIV-monoinfected patients. Adjusted incidence rate ratios (95% confidence intervals) comparing the modern to the early antiretroviral era were 0.95 (.61-1.47) for HCV, 0.95 (.40-2.26) for HBV, and 1.52 (.46-5.02) for triply infected patients. Use of antiretrovirals dually activity against HBV increased over time. However, in the modern era, 35% of HBV-coinfected patients were not receiving tenofovir. There was little use of HCV therapy.ConclusionsDespite increasing use of antiretrovirals, no clear reduction in ESLD risk was observed over 15 years. Treatment with direct-acting antivirals for HCV and wider use of tenofovir-based regimens for HBV should be prioritized for coinfected patients.

Published
2016

19. Incidence of AIDS-Defining Opportunistic Infections in a Multicohort Analysis of HIV-infected Persons in the United States and Canada, 2000–2010

Author

Buchacz, Kate, Lau, Bryan, Jing, Yuezhou, Bosch, Ronald, Abraham, Alison G, Gill, M John, Silverberg, Michael J, Goedert, James J, Sterling, Timothy R, Althoff, Keri N, Martin, Jeffrey N, Burkholder, Greer, Gandhi, Neel, Samji, Hasina, Patel, Pragna, Rachlis, Anita, Thorne, Jennifer E, Napravnik, Sonia, Henry, Keith, Mayor, Angel, Gebo, Kelly, Gange, Stephen J, Moore, Richard D, Brooks, John T, Research and Design of IeDEA, for the North American AIDS Cohort Collaboration on, Kirk, Gregory D, Benson, Constance A, Bosch, Ronald J, Boswell, Stephen, Mayer, Kenneth H, Grasso, Chris, Hogg, Robert S, Harrigan, P Richard, Montaner, Julio SG, Cescon, Angela, Gebo, Kelly A, Carey, John T, Rodriguez, Benigno, Horberg, Michael A, Jacobson, Lisa P, D'Souza, Gypsyamber, Klein, Marina B, Rourke, Sean B, Burchell, Ann N, Rachlis, Anita R, Hunter-Mellado, Robert F, Mayor, Angel M, Deeks, Steven G, Saag, Michael S, Mugavero, Michael J, Willig, James, Eron, Joseph J, Kitahata, Mari M, Crane, Heidi M, Drozd, Daniel R, Rebeiro, Peter F, Haas, David, Bebawy, Sally, Turner, Megan, Justice, Amy C, Dubrow, Robert, Fiellin, David, and Anastos, Kathryn

Subjects
Medical Microbiology, Biomedical and Clinical Sciences, Clinical Sciences, Sexually Transmitted Infections, Infectious Diseases, Clinical Research, HIV/AIDS, Infection, AIDS-Related Opportunistic Infections, Adult, Canada, Cohort Studies, Female, Humans, Incidence, Male, Middle Aged, Survival Analysis, United States, AIDS-related opportunistic infections, HIV cohort studies, incidence, prophylaxis, combination antiretroviral therapy, CD4(+) T-lymphocyte count, epidemiology, North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of IeDEA, CD4+ T-lymphocyte count, Biological Sciences, Medical and Health Sciences, Microbiology, Biological sciences, Biomedical and clinical sciences, Health sciences
Abstract

BackgroundThere are few recent data on the rates of AIDS-defining opportunistic infections (OIs) among human immunodeficiency virus (HIV)-infected patients in care in the United States and Canada.MethodsWe studied HIV-infected participants in 16 cohorts in the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) during 2000-2010. After excluding 16 737 (21%) with any AIDS-defining clinical events documented before NA-ACCORD enrollment, we analyzed incident OIs among the remaining 63 541 persons, most of whom received antiretroviral therapy during the observation. We calculated incidence rates per 100 person-years of observation (hereafter, "person-years") with 95% confidence intervals (CIs) for the first occurrence of any OI and select individual OIs during 2000-2003, 2004-2007, and 2008-2010.ResultsA total of 63 541 persons contributed 261 573 person-years, of whom 5836 (9%) developed at least 1 OI. The incidence rate of any first OI decreased over the 3 observation periods, with 3.0 cases, 2.4 cases, and 1.5 cases per 100 person-years of observation during 2000-2003, 2004-2007, and 2008-2010, respectively (Ptrend

Published
2016

24. Cumulative Incidence of Cancer Among Persons With HIV in North America: A Cohort Study.

Author

Silverberg, Michael J, Lau, Bryan, Achenbach, Chad J, Jing, Yuezhou, Althoff, Keri N, D'Souza, Gypsyamber, Engels, Eric A, Hessol, Nancy A, Brooks, John T, Burchell, Ann N, Gill, M John, Goedert, James J, Hogg, Robert, Horberg, Michael A, Kirk, Gregory D, Kitahata, Mari M, Korthuis, Philip T, Mathews, William C, Mayor, Angel, Modur, Sharada P, Napravnik, Sonia, Novak, Richard M, Patel, Pragna, Rachlis, Anita R, Sterling, Timothy R, Willig, James H, Justice, Amy C, Moore, Richard D, Dubrow, Robert, and North American AIDS Cohort Collaboration on Research and Design of the International Epidemiologic Databases to Evaluate AIDS

Subjects
North American AIDS Cohort Collaboration on Research and Design of the International Epidemiologic Databases to Evaluate AIDS, Humans, Sarcoma, Kaposi, HIV Infections, Neoplasms, Lymphoma, Non-Hodgkin, Colorectal Neoplasms, Anus Neoplasms, Liver Neoplasms, Lung Neoplasms, Incidence, Proportional Hazards Models, Cohort Studies, Comorbidity, Age Distribution, Adult, Aged, Middle Aged, North America, Female, Male, Sarcoma, Kaposi, Lymphoma, Non-Hodgkin, General & Internal Medicine, Medical and Health Sciences
Abstract

BackgroundCancer is increasingly common among persons with HIV.ObjectiveTo examine calendar trends in cumulative cancer incidence and hazard rate by HIV status.DesignCohort study.SettingNorth American AIDS Cohort Collaboration on Research and Design during 1996 to 2009.Participants86 620 persons with HIV and 196 987 uninfected adults.MeasurementsCancer type-specific cumulative incidence by age 75 years and calendar trends in cumulative incidence and hazard rates, each by HIV status.ResultsCumulative incidences of cancer by age 75 years for persons with and without HIV, respectively, were as follows: Kaposi sarcoma, 4.4% and 0.01%; non-Hodgkin lymphoma, 4.5% and 0.7%; lung cancer, 3.4% and 2.8%; anal cancer, 1.5% and 0.05%; colorectal cancer, 1.0% and 1.5%; liver cancer, 1.1% and 0.4%; Hodgkin lymphoma, 0.9% and 0.09%; melanoma, 0.5% and 0.6%; and oral cavity/pharyngeal cancer, 0.8% and 0.8%. Among persons with HIV, calendar trends in cumulative incidence and hazard rate decreased for Kaposi sarcoma and non-Hodgkin lymphoma. For anal, colorectal, and liver cancer, increasing cumulative incidence, but not hazard rate trends, were due to the decreasing mortality rate trend (-9% per year), allowing greater opportunity to be diagnosed. Despite decreasing hazard rate trends for lung cancer, Hodgkin lymphoma, and melanoma, cumulative incidence trends were not seen because of the compensating effect of the declining mortality rate.LimitationSecular trends in screening, smoking, and viral co-infections were not evaluated.ConclusionCumulative cancer incidence by age 75 years, approximating lifetime risk in persons with HIV, may have clinical utility in this population. The high cumulative incidences by age 75 years for Kaposi sarcoma, non-Hodgkin lymphoma, and lung cancer support early and sustained antiretroviral therapy and smoking cessation.

Published
2015

25. Disparities in the Quality of HIV Care When Using US Department of Health and Human Services Indicators

Author

Althoff, Keri N, Rebeiro, Peter, Brooks, John T, Buchacz, Kate, Gebo, Kelly, Martin, Jeffrey, Hogg, Robert, Thorne, Jennifer E, Klein, Marina, Gill, M John, Sterling, Timothy R, Yehia, Baligh, Silverberg, Michael J, Crane, Heidi, Justice, Amy C, Gange, Stephen J, Moore, Richard, Kitahata, Mari M, Horberg, Michael A, Research and Design, for the North American AIDS Cohort Collaboration on, Kirk, Gregory D, Benson, Constance A, Bosch, Ronald J, Collier, Ann C, Boswell, Stephen, Grasso, Chris, Mayer, Kenneth H, Hogg, Robert S, Harrigan, P Richard, Montaner, Julio SG, Cescon, Angela, Samji, Hasina, Gebo, Kelly A, Moore, Richard D, Carey, John T, Goedert, James J, Jacobson, Lisa P, Klein, Marina B, Rourke, Sean B, Burchell, Ann N, Rachlis, Anita R, Hunter-Mellado, Robert F, Mayor, Angel M, Deeks, Steven G, Martin, Jeffrey N, Saag, Michael S, Mugavero, Michael J, Willig, James, Eron, Joseph J, Napravnik, Sonia, Crane, Heidi M, Dubrow, Robert, Fiellin, David, Haas, David, Bebawy, Sally, Turner, Megan, Anastos, Kathryn, McKaig, Rosemary G, Freeman, Aimee M, Lent, Carol, Van Rompaey, Stephen E, Morton, Liz, McReynolds, Justin, Lober, William B, Abraham, Alison G, Lau, Bryan, Zhang, Jinbing, Jing, Jerry, Golub, Elizabeth, Modur, Shari, Hanna, David B, Wong, Cherise, and Mendes, Adell

Subjects
Medical Microbiology, Biomedical and Clinical Sciences, Infectious Diseases, Behavioral and Social Science, Prevention, Sexually Transmitted Infections, Health Services, Women's Health, HIV/AIDS, Clinical Research, Infection, Good Health and Well Being, Adult, Aged, Aged, 80 and over, Anti-Retroviral Agents, Cohort Studies, Continuity of Patient Care, Cross-Sectional Studies, Female, HIV Infections, Healthcare Disparities, Humans, Male, Middle Aged, United States, United States Dept. of Health and Human Services, Viral Load, HIV, quality of care, retention in care, antiretroviral therapy, HIV RNA suppression, North American AIDS Cohort Collaboration on Research and Design, Biological Sciences, Medical and Health Sciences, Microbiology, Clinical sciences
Abstract

We estimated US Department of Health and Human Services (DHHS)-approved human immunodeficiency virus (HIV) indicators. Among patients, 71% were retained in care, 82% were prescribed treatment, and 78% had HIV RNA ≤200 copies/mL; younger adults, women, blacks, and injection drug users had poorer outcomes. Interventions are needed to reduce retention- and treatment-related disparities.

Published
2014

27. Trends in infection-related and infection-unrelated cancer incidence among people with and without HIV infection in Ontario, Canada, 1996–2020: a population-based matched cohort study using health administrative data

Author

Nicolau, Ioana A., primary, Moineddin, Rahim, additional, Antoniou, Tony, additional, Brooks, Jennifer D., additional, Gillis, Jennifer L., additional, Kendall, Claire E., additional, Cooper, Curtis, additional, Cotterchio, Michelle, additional, Salters, Kate, additional, Smieja, Marek, additional, Kroch, Abigail E., additional, Lindsay, Joanne D., additional, Price, Colleen, additional, Mohamed, Anthony, additional, and Burchell, Ann N., additional

Published
2023
Full Text
View/download PDF

31. Closing the Gap: Increases in Life Expectancy among Treated HIV-Positive Individuals in the United States and Canada

Author

Samji, Hasina, Cescon, Angela, Hogg, Robert S, Modur, Sharada P, Althoff, Keri N, Buchacz, Kate, Burchell, Ann N, Cohen, Mardge, Gebo, Kelly A, Gill, M John, Justice, Amy, Kirk, Gregory, Klein, Marina B, Korthuis, P Todd, Martin, Jeff, Napravnik, Sonia, Rourke, Sean B, Sterling, Timothy R, Silverberg, Michael J, Deeks, Stephen, Jacobson, Lisa P, Bosch, Ronald J, Kitahata, Mari M, Goedert, James J, Moore, Richard, Gange, Stephen J, and Research and Design of IeDEA, for The North American AIDS Cohort Collaboration on

Subjects
Biomedical and Clinical Sciences, Public Health, Health Sciences, Human Society, Clinical Sciences, Behavioral and Social Science, Infectious Diseases, Aging, Sexually Transmitted Infections, Clinical Research, HIV/AIDS, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Infection, Good Health and Well Being, Adult, Canada, Female, HIV Infections, Humans, Life Expectancy, Male, Middle Aged, United States, Young Adult, North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of IeDEA, General Science & Technology
Abstract

BackgroundCombination antiretroviral therapy (ART) has significantly increased survival among HIV-positive adults in the United States (U.S.) and Canada, but gains in life expectancy for this region have not been well characterized. We aim to estimate temporal changes in life expectancy among HIV-positive adults on ART from 2000-2007 in the U.S. and Canada.MethodsParticipants were from the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD), aged ≥20 years and on ART. Mortality rates were calculated using participants' person-time from January 1, 2000 or ART initiation until death, loss to follow-up, or administrative censoring December 31, 2007. Life expectancy at age 20, defined as the average number of additional years that a person of a specific age will live, provided the current age-specific mortality rates remain constant, was estimated using abridged life tables.ResultsThe crude mortality rate was 19.8/1,000 person-years, among 22,937 individuals contributing 82,022 person-years and 1,622 deaths. Life expectancy increased from 36.1 [standard error (SE) 0.5] to 51.4 [SE 0.5] years from 2000-2002 to 2006-2007. Men and women had comparable life expectancies in all periods except the last (2006-2007). Life expectancy was lower for individuals with a history of injection drug use, non-whites, and in patients with baseline CD4 counts

Published
2013

33. Community and Health Care Provider Preferences for Bacterial Sexually Transmitted Infection Testing Interventions for Gay, Bisexual, and Other Men Who Have Sex With Men: e-Delphi Study

Author

Yeung, Anna, primary, Lisk, Ryan, additional, Rana, Jayoti, additional, Guiang, Charlie B, additional, Bacon, Jean, additional, Brunetta, Jason, additional, Gilbert, Mark, additional, Gesink, Dionne, additional, Grewal, Ramandip, additional, Kwag, Michael, additional, Logie, Carmen H, additional, Mitterni, Leo, additional, Shahin, Rita, additional, Tan, Darrell HS, additional, and Burchell, Ann N, additional

Published
2023
Full Text
View/download PDF

41. Acceptability of an existing online sexually transmitted and blood-borne infection testing model among gay, bisexual and other men who have sex with men in Ontario, Canada

Author

Dulai, Joshun JS, primary, Gilbert, Mark, additional, Lachowsky, Nathan J, additional, Card, Kiffer G, additional, Klassen, Ben, additional, Dame, Jessy, additional, Burchell, Ann N, additional, Worthington, Catherine, additional, Ablona, Aidan, additional, Anand, Praney, additional, Blaque, Ezra, additional, Ryu, Heeho, additional, Stewart, MacKenzie, additional, Brennan, David J, additional, and Grace, Daniel, additional

Published
2023
Full Text
View/download PDF

42. COVID-19 vaccine immunogenicity in people with HIV

Author

Costiniuk, Cecilia T., primary, Singer, Joel, additional, Lee, Terry, additional, Langlois, Marc-André, additional, Arnold, Corey, additional, Galipeau, Yannick, additional, Needham, Judy, additional, Kulic, Iva, additional, Jenabian, Mohammad-Ali, additional, Burchell, Ann N., additional, Shamji, Hasina, additional, Chambers, Catharine, additional, Walmsley, Sharon, additional, Ostrowski, Mario, additional, Kovacs, Colin, additional, Tan, Darrell H.S., additional, Harris, Marianne, additional, Hull, Mark, additional, Brumme, Zabrina L., additional, Lapointe, Hope R., additional, Brockman, Mark A., additional, Margolese, Shari, additional, Mandarino, Enrico, additional, Samarani, Suzanne, additional, Vulesevic, Branka, additional, Lebouché, Bertrand, additional, Angel, Jonathan B., additional, Routy, Jean-Pierre, additional, Cooper, Curtis L., additional, and Anis, Aslam H., additional

Published
2022
Full Text
View/download PDF

44. sj-docx-1-dhj-10.1177_20552076231173557 - Supplemental material for Acceptability of an existing online sexually transmitted and blood-borne infection testing model among gay, bisexual and other men who have sex with men in Ontario, Canada

Author

Dulai, Joshun JS, Gilbert, Mark, Lachowsky, Nathan J, Card, Kiffer G, Klassen, Ben, Dame, Jessy, Burchell, Ann N, Worthington, Catherine, Ablona, Aidan, Anand, Praney, Blaque, Ezra, Ryu, Heeho, Stewart, MacKenzie, Brennan, David J, and Grace, Daniel

Subjects
FOS: Computer and information sciences, 200299 Cultural Studies not elsewhere classified, Science Policy, FOS: Clinical medicine, FOS: Political science, 150310 Organisation and Management Theory, Cardiology, 111799 Public Health and Health Services not elsewhere classified, FOS: Health sciences, 110306 Endocrinology, 110308 Geriatrics and Gerontology, 99999 Engineering not elsewhere classified, FOS: Sociology, FOS: Economics and business, 111099 Nursing not elsewhere classified, FOS: Other engineering and technologies, Sociology, 111708 Health and Community Services, Anthropology, 111702 Aged Health Care, 89999 Information and Computing Sciences not elsewhere classified, FOS: Other humanities, 160512 Social Policy, 111299 Oncology and Carcinogenesis not elsewhere classified
Abstract

Supplemental material, sj-docx-1-dhj-10.1177_20552076231173557 for Acceptability of an existing online sexually transmitted and blood-borne infection testing model among gay, bisexual and other men who have sex with men in Ontario, Canada by Joshun JS Dulai, Mark Gilbert, Nathan J Lachowsky, Kiffer G Card, Ben Klassen, Jessy Dame, Ann N Burchell, Catherine Worthington, Aidan Ablona, Praney Anand, Ezra Blaque, Heeho Ryu, MacKenzie Stewart, David J Brennan and Daniel Grace in DIGITAL HEALTH

Published
2023
Full Text
View/download PDF

45. Coronavirus disease 2019 vaccine effectiveness among a population-based cohort of people living with HIV

Author

Chambers, Catharine, primary, Samji, Hasina, additional, Cooper, Curtis L., additional, Costiniuk, Cecilia T., additional, Janjua, Naveed Z., additional, Kroch, Abigail E., additional, Arbess, Gordon, additional, Benoit, Anita C., additional, Buchan, Sarah A., additional, Chung, Hannah, additional, Kendall, Claire E., additional, Kwong, Jeffrey C., additional, Langlois, Marc-André, additional, Lee, Samantha M., additional, Mbuagbaw, Lawrence, additional, McCullagh, John, additional, Moineddin, Rahim, additional, Nambiar, Devan, additional, Walmsley, Sharon, additional, Anis, Aslam H., additional, and Burchell, Ann N., additional

Published
2022
Full Text
View/download PDF

46. Prevalence of Physical Health, Mental Health, and Disability Comorbidities among Women Living with HIV in Canada

Author

Heer, Emily, primary, Kaida, Angela, additional, O’Brien, Nadia, additional, Kleiner, Bluma, additional, Pierre, Alie, additional, Rouleau, Danielle, additional, Burchell, Ann N., additional, Skerritt, Lashanda, additional, Proulx-Boucher, Karène, additional, Nicholson, Valerie, additional, Loutfy, Mona, additional, and de Pokomandy, Alexandra, additional

Published
2022
Full Text
View/download PDF

47. The burden of cancer among people living with HIV in Ontario, Canada, 1997–2020: a retrospective population-based cohort study using administrative health data

Author

Nicolau, Ioana A., primary, Antoniou, Tony, additional, Brooks, Jennifer D., additional, Moineddin, Rahim, additional, Cooper, Curtis, additional, Cotterchio, Michelle, additional, Gillis, Jennifer L., additional, Kendall, Claire E., additional, Kroch, Abigail E., additional, Lindsay, Joanne D., additional, Price, Colleen, additional, Salters, Kate, additional, Smieja, Marek, additional, and Burchell, Ann N., additional

Published
2022
Full Text
View/download PDF

48. Factors and Priorities Influencing Satisfaction with Care among Women Living with HIV in Canada: A Fuzzy Cognitive Mapping Study

Author

Skerritt, Lashanda, primary, Kaida, Angela, additional, Savoie, Édénia, additional, Sánchez, Margarite, additional, Sarmiento, Iván, additional, O’Brien, Nadia, additional, Burchell, Ann N., additional, Bartlett, Gillian, additional, Boucoiran, Isabelle, additional, Kestler, Mary, additional, Rouleau, Danielle, additional, Loutfy, Mona, additional, and de Pokomandy, Alexandra, additional

Published
2022
Full Text
View/download PDF

49. Disclosure of HIV-serodiscordant relationships and association with viral suppression: results from the Positive Plus One study

Author

Mendelsohn, Joshua B, Calzavara, Liviana, Bullock, Sandra, Iveniuk, James, Tan, Darrell HS, Burchell, Ann N, Bourne, Adam, Lebouché, Bertrand, Daftary, Amrita, Moravan, Veronika, Loutfy, Mona, Conway, Brian, and Positive Plus One Study Team

Abstract

BACKGROUND: Little is known about the effects of disclosure of HIV-serodiscordant relationships on clinical outcomes. We aimed to evaluate the effect of relationship disclosure on HIV viral suppression, and hypothesized that disclosure by HIV-positive and HIV-negative partners would be associated with viral suppression in the HIV-positive partner. METHODS: We conducted a Canadian national online and telephone-administered survey of HIV-positive and HIV-negative partners in serodiscordant relationships. The primary outcome was self-reported viral suppression. Multivariable analyses were undertaken using Firth logistic regression. RESULTS: We recruited 540 participants in current serodiscordant relationships (n = 228 HIV-negative; n = 312 HIV-positive). Similar proportions of HIV-positive and HIV-negative partners disclosed their relationship to healthcare professionals (82% v. 76%, p = 0.13). Among HIV-positive partners, disclosure of the relationship to healthcare professionals increased the odds of viral suppression (aOR = 4.7; CI: 2.13, 10.51) after adjusting for age, education, and relationship turmoil due to HIV. Increasing age (aOR = 1.28; 95% CI = 1.07, 1.55) and education (aOR = 2.43; 95% CI = 1.15, 5.26) were also associated with viral suppression. Among HIV-negative partners, relationship disclosure was not associated with viral suppression and HIV-negative heterosexual men were less likely to report that their HIV-positive partners were virally suppressed (aOR = 0.24; CI: 0.09, 0.61). CONCLUSIONS: Disclosure of HIV-serodiscordant status by HIV-positive participants to healthcare professionals was associated with increased odds of viral suppression. Similar effects were not evident among HIV-negative participants. Future work should explore factors that empower relationship disclosure and incorporate them into supportive services for HIV-serodiscordant relationships.

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results